Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease

Trial Profile

Phase I Dose-Escalation Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of a Topical Compound 31543 (Calcitriol, USP) in Adult Cancer Patients Receiving Taxane-based Chemotherapy Regimens for the Treatment of Advanced or Recurrent Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Calcitriol (Primary)
  • Indications Alopecia
  • Focus Adverse reactions
  • Sponsors Berg Pharma
  • Most Recent Events

    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 Results presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to a BERG media release.
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top